Transaction #1272 · Form 4 · 0001214659-25-015048
Aquestive Therapeutics, Inc. · Exercise / conversion · Common Stock
Aquestive Therapeutics, Inc. · Transacted October 15, 2025 · Filed October 17, 2025
What does this filing report?
An SEC Form 4 filing for Aquestive Therapeutics, Inc. records an exercise / conversion involving Common Stock on October 15, 2025. The reported quantity was 25,000. The filing date is October 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Aquestive Therapeutics, Inc.
- Company CIK
- 0001398733
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 25,000
- Reported price
- 3.1027
- Reference value
- 77,567.5
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 308,346
- Ownership description
- Not reported
- SEC acceptance time
- Oct 17, 2025, 2:01 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Jung Cassie ↗
Chief Operating Officer
CIK 0001960154
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
- F2
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
- F3
- This option was granted on June 10, 2021 and is fully vested.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.